<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Pharma Trend</provider_name><provider_url>https://pharma-trend.com/en</provider_url><author_name>Business Wire</author_name><author_url>https://pharma-trend.com/en/author/business/</author_url><title>Babylon Denies Acquisition Rumors - Pharma Trend</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="6cXWmijsJE"&gt;&lt;a href="https://pharma-trend.com/en/babylon-denies-acquisition-rumors/"&gt;Babylon Denies Acquisition Rumors&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://pharma-trend.com/en/babylon-denies-acquisition-rumors/embed/#?secret=6cXWmijsJE" width="600" height="338" title="&#x201C;Babylon Denies Acquisition Rumors&#x201D; &#x2014; Pharma Trend" data-secret="6cXWmijsJE" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://pharma-trend.com/en/wp-includes/js/wp-embed.min.js
/* ]]&gt; */
&lt;/script&gt;
</html><description>AUSTIN, Texas &amp; LONDON&#x2013;(BUSINESS WIRE)&#x2013;Babylon Holdings Limited (NYSE: BBLN) (&#x201C;Babylon&#x201D; or the &#x201C;Company&#x201D;), one of the world&#x2019;s fastest-growing digital healthcare companies, today announced that it is not engaged in nor has it had contact or discussions with any potential acquirer. The Company is actively working with the staff of the NYSE to resume trading as ... [Read more...]</description><thumbnail_url>https://mms.businesswire.com/media/20220815005673/en/1544640/21/Babylon_Logo_Horizontal_Violet_CMYK.jpg</thumbnail_url></oembed>
